| Project/Area Number |
15K18452
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 非小細胞肺癌 / ALK融合遺伝子 / ALK阻害剤 / 耐性機序 / 肺癌 / 次世代ALK阻害剤 / 耐性獲得機序 |
|---|
| Outline of Final Research Achievements |
Previous preclinical and clinical studies have identified various resistance mechanisms, such as secondary mutations in the ALK gene and the activation of bypass tracks. In the current study, novel ALK secondary mutations including I1171T/N and G1123S were shown to confer resistance against crizotinib, alectinib and ceritinib. Furthermore, we showed that MET amplification might mediate alectinib resistance, which could be overcome by crizotinib, a first generation ALK inhibitor. These findings are important for the optimal treatemnt strategies to overcome resistances against ALK inhibitors.
|
